publication . Article . Other literature type . Part of book or chapter of book . 2011

Treatment of multiple sclerosis.

M. Nadeem; O. Mufti; I. Ahsan; R. Naheed; S. M. Faheem;
Open Access English
  • Published: 01 Jan 2011 Journal: Annals of Indian Academy of Neurology, volume 14, issue Suppl1, pages S65-S69 (issn: 0972-2327, eissn: 1998-3549, Copyright policy)
  • Publisher: Medknow Publications
Abstract
Multipla skleroza (MS) je upalna autoimuna demijelinizacijska bolest središnjega živčanog sustava obilježena multifokalnom upalnom destrukcijom mijelina, oštećenjem aksona i gubitkom oligodendrocita. Bolest se odvija kroz dvije faze, upalnu i degenerativnu. Najčešći oblik bolesti, u otprilike 85% slučajeva je RRMS (relapsno-remitentni oblik). Liječenje MS dijeli se na liječenje akutne faze bolesti, prevenciju novih recidiva i progresije bolesti te simptomatsko liječenje. Posljednjih godina najviše promjena i novih lijekova u liječenju multiple skleroze rabi se u liječenju odnosno sprječavanju progresije bolesti te prevenciji recidiva bolesti. Neki od tih lijekov...
Subjects
free text keywords: Guidelines, Multiple sclerosis - therapy; Immunosuppressive agents - therapeutic use; Interferon, beta - therapeutic use, Multipla skleroza - terapija;Imunosupresivi - terapijska primjena; Interferon, beta - terapijska primjena, Important Advances in Clinical Medicine, Correspondence, Neurology. Diseases of the nervous system, RC346-429, General Medicine, Emergency medicine, medicine.medical_specialty, medicine, business.industry, business, Multiple sclerosis, medicine.disease, Surgery, Chemotherapy, medicine.medical_treatment, Diabetes mellitus, Clinical Neurology, Epidemiology, Disease, Inflammatory disorder, Natural history, Pathology, Ascorbic acid, B cell, medicine.anatomical_structure, Immunology, Oral administration, CD20, biology.protein, biology, CD19, Arts and Humanities (miscellaneous), Western hemisphere, Clinical trial, Computed tomographic, Physical therapy, Recall, Solution focused brief therapy, Anesthesia, Suppressor cell, Pediatrics, Cyclophosphamide, medicine.drug, Alternative medicine, Adrenocorticotropic hormone, Immunosuppression, Internal medicine, General Neuroscience, Pharmacology, Oncology, Demyelinating disease, Young adult, Pharmacotherapy, Pathological, Methylprednisolone, Disease progression, Immune system, Intensive care medicine, Clinical research, Adverse effect
Related Organizations
27 references, page 1 of 2

1. Choffion M. Mechanisms of action for treatments in multiple sclerosis. Biodrugs 2005;19:299-308

2. Isaacs A, Lindemann J. Virus interference. The interferon. Proc R Soc Lond (BioI) 1957;147;258-67

3. Iz rada struene grupe za lijekove Ministarstva zdravstva Republike Hrvatske. Pharmaca 1997;35:49-60

4. The IFNB MS Study Group.Interferon beta -Ib is effective in RRlVIS: clinical results of a multicentre, randomized, doubleblind, plecebo-controlled trial. Neurology 1993;43:665-61

5. Filippini G, Munari L, Incorvaia B, Ebers GC, Polman C, DAmico R. Interferons in relapsing rmitting multiple sclerosis: a systematic review. Lancet 2003;361:545-52

6. ShariefMK. Dose and frequency of administration of interferon-beta affect its efficacy in multiple sclerosis. Clin drug Investig 2003;23:551-9

7. The PRISMS Study Group (Prevention of Relapses and Disability by Interferon Beta-la Subcutaneously in Multiple Sclerosis). Randomised double-blind placebo controlled study of interferon beta-la in relapsing/remitting multiple sclerosis . Lancet 1988;352:1498-504

8. Jacobs LD, Cookfair DL, Rudick RA. Results of a phase III trialof intramuscular recombinant beta interferon as treatmentof mul tiple sclerosis. Ann NeuroI1994;36:256 ???

9. Jacobs LD, Cookfair DL, Rudick RA. Intramuscular interferon-beta la for a disease progression in relapsing multiple sclerosis. Ann NeuroI1996;39:258-94

10. IFNB MS Study Group. Interferon beta-lb is effective in relapsing-remitting multiple sclerosis. I MRI analysis results of a multicentre, randomized, double-blind, placebo-controlled trial. Neurology 1993;43:662-667

11. Kappos L. New aspects in the treatment of multiple sclerosis with interferon beta lb.]NeuroI2004;251(SuppI4):IV/l;DOI 10.1007/00415-004-1401-4

12. Durelli L. Is multiple sclerosis a disease that requires frequent beta interferon dosing? ] Neurol 2004;251(Suppl 4): IV/13­ IV/24;DOI10.1007/00415-004-1404-1 [OpenAIRE]

13. Comi G, Filippi M, BarkhofF, Durelli L, Edan G, Fernandez 0 et al. Effect of early interferon treatment on conversion to definite multiple sclerosis: a randomised study. Lancet 2001; 357;1576-82 [OpenAIRE]

14. Galetta SL. The Controlled High Risk Avonex Multiple Sclerosis Trial (CHAlVIPS study). J Neuroophthalmol 2001;21;292-5

15. Kappos L, Polman CH , Freedman MS, Edan G, Hartung HP, Miller DH et al. Treatment with interferon beta-lb delays conversion t clinically definite and McDonald MS in patients with clinically isolated syndromes. Neurology 2006;67;1242-9

27 references, page 1 of 2
Powered by OpenAIRE Open Research Graph
Any information missing or wrong?Report an Issue
publication . Article . Other literature type . Part of book or chapter of book . 2011

Treatment of multiple sclerosis.

M. Nadeem; O. Mufti; I. Ahsan; R. Naheed; S. M. Faheem;